Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
AFMDAffimed(AFMD) Newsfilter·2024-01-09 05:05

Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohortFollow-up shows three of the initially reported responses have now been confirmed (1 CR, 2 PR) and one still awaiting a confirmatory scanStudy to be expanded to a total of 40 EGFRwt NSCLC patientsEnrollment in the EGFR-mutant (mut) NSCLC cohort is ongoingData from both the EGFRwt and EGFRmut cohorts expected in H1 2024 MANNHEIM, Germa ...